Ozempic Savings & Cost Guide (2026)
Ozempic is FDA-approved for type 2 diabetes, cardiovascular risk reduction in T2D, and kidney disease in T2D. List price $1,027.51/mo; insured rate as low as $25. Verified monthly.
Ozempic (semaglutide) is Novo Nordisk's FDA-approved GLP-1 for type 2 diabetes, cardiovascular risk reduction in adults with T2D and established heart disease, and slowing kidney disease progression in T2D with CKD. List price is $1,027.51 per 28-day supply (uniform across all doses). With commercial insurance covering Ozempic for its FDA-approved use, the Savings Card brings out-of-pocket cost as low as $25 per month. Uninsured patients new to the offer pay $199 per month for the first 2 fills of 0.25 mg or 0.5 mg, then $349 per month for 0.25 to 1 mg doses or $499 per month for the 2 mg dose. The Novo Nordisk Patient Assistance Program offers free Ozempic for income-eligible patients. Patients seeking semaglutide for weight loss should consider Wegovy, the FDA-approved weight-loss version of the same molecule.
Looking for semaglutide for weight loss? Use Wegovy, not Ozempic.
Wegovy is the same molecule as Ozempic (semaglutide), FDA-approved for chronic weight management. Insurance coverage is better, and NovoCare Pharmacy offers a cash-pay pill at $149/month that Ozempic does not.
What is Ozempic?
Ozempic is the brand name for semaglutide when prescribed for type 2 diabetes. It is a once-weekly subcutaneous injection activating the GLP-1 receptor. FDA-approved indications: glycemic control in adults with type 2 diabetes, cardiovascular risk reduction in adults with T2D and established heart disease, and slowing kidney disease progression in adults with T2D and chronic kidney disease.
Ozempic and Wegovy contain the same active ingredient (semaglutide), made by the same manufacturer. The difference is FDA-approved indication, which changes what insurance covers and which savings programs you qualify for.
Pricing snapshot
As low as $25/mo with insurance, $199/mo new-patient cash-pay, $349 to $499/mo standard self-pay, up to $1,027.51/mo at list price.
Explore the guide
Two dedicated pages cover the Savings Card, cash-pay pricing, and the monthly cost breakdown by dose.
Recent pricing news
Self-pay program launch, federal pricing framework, and patent timeline.
- November 17, 2025
Uninsured / self-pay introductory pricing launched
Novo Nordisk launched a limited-time introductory offer for uninsured and self-pay patients: $199/month for the first 2 monthly fills of Ozempic 0.25 mg or 0.5 mg. Valid November 17, 2025 through June 30, 2026. After the intro period, pricing reverts to $349/month for 0.25-1 mg or $499/month for 2 mg.
- November 6, 2025In progress
Most-Favored-Nation (MFN) pricing framework announced
Federal framework tying U.S. GLP-1 prices to lowest prices paid in comparable countries. Impact for Ozempic: Medicare Part D enrollees with type 2 diabetes coverage may see copays capped at approximately $50/month for eligible beneficiaries. Implementation in progress through 2026.
Status: Announced, implementation in progress.
- Invalid DateIn progress
Patent expiration (generic semaglutide eligibility)
Ozempic is patent-protected through 2031 per Novo Nordisk disclosures (per SingleCare reporting). Generic semaglutide cannot launch for Ozempic until the patent expires. No generic currently available or imminent.
Status: Anticipated. Monitor FDA approvals annually.
Frequently asked
Top questions about Ozempic access and cost. Full FAQ on the coupon page.
Compare with other GLP-1s
Pricing verified against Novo Nordisk's official ozempic.com and novocare.com pages, cross-referenced with GoodRx, SingleCare, Optum Perks, and Weight Watchers. We do not accept payment for inclusion in any comparison. Medical content reviewed by Dr. Golsa Gholampour, MD, board-certified in obesity medicine. Quarterly re-verification scheduled.